- Supported exchanges /
- F /
- 7AL.F
ALLIGATOR BIOSC. AB O.N. (7AL F) stock market data APIs
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company's product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, an immunostimulatory antibody, which is in phase 1 clinical trial for the treatment of metastatic cancer. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus Inc.; BioArctic AB; and Abclon Inc. The company was founded in 2000 and is headquartered in Lund, Sweden.
ALLIGATOR BIOSC. AB O.N. Financial Data Overview
0.0646 | |
0.082 | |
- | |
0.082 | |
0.0646 | |
0.0226-0.1316 | |
55 821 K | |
758 M | |
27 774 K | |
1.35 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ALLIGATOR BIOSC. AB O.N. Fundamental Data is available in our Financial Data APIs
- Net Revenue 27 774 K
- EBITDA -239 715 008
- Earnings Per Share -0.03
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ALLIGATOR BIOSC. AB O.N. Earnings via APIs
- Latest Release 2024-10-24
- EPS/Forecast NaN
Get ALLIGATOR BIOSC. AB O.N. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: